This bill bars insurers from using someone’s status as a living organ donor as a basis to deny coverage, cancel a policy, or increase premiums — unless the insurer can point to an actual, unique, and material actuarial risk tied to the donation. The measure covers life, disability, and qualified long-term care policies.
Beyond underwriting limits, the legislation directs the Department of Health and Human Services to refresh public-facing educational material within six months to explain donation risks, benefits, and how donation may affect access to insurance. The law leaves enforcement to state insurance regulators rather than creating a new federal private right of action.
At a Glance
What It Does
The bill forbids insurers from varying any term, rate, or issuance decision on life, disability, or long-term care policies based solely on an individual’s status as a living organ donor, unless an insurer demonstrates an actual, unique, and material actuarial risk. It also requires HHS to update educational outreach about donation and insurance impacts.
Who It Affects
Primary targets are life, disability, and long-term care insurers and their underwriters, state insurance regulators charged with enforcement, transplant programs that advise prospective donors, and individuals who have donated or plan to donate an organ.
Why It Matters
The measure reduces a documented barrier to living donation — insurers pricing or denying coverage — and creates a uniform federal standard that restricts certain underwriting practices while preserving state-based enforcement. Compliance and consumer outreach will be operational tasks for insurers, regulators, and transplant centers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a federal prohibition on insurance decisions that treat living organ donors as a disfavored class. Under the text, an insurer may not refuse to issue coverage, cancel coverage, set premiums, or otherwise change a life, disability, or qualified long-term care policy on the basis of someone’s status as a living organ donor unless the insurer can identify an actual, unique, and material actuarial risk specifically tied to that donor status.
That is a narrow exception; the plain-language standard requires more than speculative or generic underwriting concerns.
For enforcement, the law does not authorize a new federal enforcement mechanism or private cause of action. Instead, it contemplates enforcement through existing state insurance regulatory systems — state regulators retain the authority given under their laws to police insurer behavior.
The bill also clarifies covered policy types and provides definitions (for example, it ties the long-term care definition to the Internal Revenue Code reference for qualified long-term care services) so insurers and regulators know the scope.Separately, the Department of Health and Human Services must review and refresh publicly available materials about living donation within six months. The update must address both medical benefits and risks and the practical insurance implications of donation, and the agency may use PSAs, organdonor.gov or successor sites, and other media it deems appropriate.
That outreach is explicitly meant to inform potential donors about legal protections and residual insurance considerations.Operationally, the text will force insurers to document underwriting decisions and to avoid relying on donor status as a proxy for risk. Transplant programs will likely need to update donor counseling to reflect the new statutory protections and the updated HHS materials.
Because enforcement is left to states, implementation will be uneven depending on regulator capacity and interpretive choices about what constitutes an ‘‘actual, unique, and material’’ actuarial risk.
The Five Things You Need to Know
The bill disallows insurers from denying coverage, canceling coverage, refusing to issue, or varying price or any policy term for life, disability, or qualified long-term care policies based solely on living organ donor status.
The statutory exception permits differential treatment only where an insurer demonstrates an actual, unique, and material actuarial risk attributable to donor status.
Enforcement is delegated to state insurance regulators under their existing statutory powers; the Act does not establish a federal private right of action or a new federal enforcement agency.
The Act defines covered products and the term ‘‘living organ donor’’ and ties the long-term care definition to section 7702B(c) of the Internal Revenue Code for qualified long-term care services.
HHS must review and update public education materials on living donation — including benefits, risks, and insurance impacts — within six months and may use the agency’s websites, PSAs, and other media.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s name: the Living Donor Protection Act of 2025. This is the caption under which regulations, guidance, and enforcement references will appear; it also signals legislative intent to treat living donor protections as a discrete policy objective.
Substantive underwriting prohibition
Imposes the central constraint on insurer behavior: no denial, cancellation, refusal to issue, pricing decision, or other change to policy terms may be based solely on an individual’s status as a living organ donor. The operative statutory language restricts insurers from using donor status as a proxy for risk, forcing underwriting to be tied to demonstrable actuarial factors.
State enforcement framework
Specifies that state insurance regulators may take actions to enforce the underwriting prohibition as authorized by state law. Practically, this preserves state supervisory channels (market conduct exams, cease-and-desist, fines) and avoids creating a federal enforcement regime or private civil remedy, which shapes the compliance pathways insurers will face.
Definitions and scope of covered products
Delivers working definitions: it defines ‘‘living organ donor’’ as an individual who donated all or part of an organ and is not deceased, and it sets out what counts as life, disability, and long-term care policies—linking long-term care to the IRC 7702B(c) qualified services. Those definitions limit confusion about which products and individuals fall under the protection.
HHS educational update requirement
Directs the Secretary of Health and Human Services to review and update public materials on living donation within six months. The update must cover medical benefits and risks and explain how donation may affect insurance access; HHS is instructed to refresh PSAs, the agency’s organ-donation web presence, and other outreach channels at its discretion, which creates an informational complement to the underwriting protections.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Prospective and recent living organ donors — they gain statutory protection against being denied life, disability, or long-term care coverage or charged higher premiums solely because they donated.
- Transplant programs and donor advocates — clearer insurance protections lower a known barrier to donation and should simplify donor counseling and recruitment messaging.
- Consumers considering donation — the HHS outreach requirement supplies standardized educational content about risks and insurance implications, reducing informational asymmetries that deter donation.
Who Bears the Cost
- Life, disability, and long-term care insurers — they face tighter limits on underwriting levers tied to donor status and may need to revise underwriting manuals, train staff, and document actuarial bases for any donor-related exceptions.
- State insurance departments — regulators must investigate and enforce compliance under existing budgets and authorities, which could increase workload without additional federal funding.
- Smaller or specialized insurers — compliance burden (policy amendments, staff training, market conduct examination preparedness) will be proportionally larger for entities with limited regulatory infrastructure.
Key Issues
The Core Tension
The bill balances donor protection against insurers’ need to price risk accurately: it prevents categorical discrimination by donor status but preserves an actuarial safety valve. Reasonable stakeholders can disagree about where to draw that line—protecting donors from blunt refusals while not preventing insurers from responding to real, demonstrable post-donation health risks.
Several implementation challenges and trade-offs merit attention. First, the statutory exception—allowing insurers to act where there is an ‘‘actual, unique, and material actuarial risk’’—is conceptually clear but operationally vague.
Regulators will need to develop standards or precedent to determine what level of evidence satisfies that threshold, and until they do, insurers may act conservatively or test boundaries in the absence of uniform guidance.
Second, the Act leaves enforcement entirely to states, creating a risk of patchwork interpretation and uneven protection across jurisdictions. Some state regulators may treat donor-status protections as strictly mandatory, while others may permit broader underwriting discretion.
The absence of a federal private right of action also limits remedies for individuals in states with less aggressive enforcement. Finally, the HHS education mandate is unfunded and short-timed (six months), which could constrain the scope and quality of outreach; agencies will have to prioritize content and channels within existing resources.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.